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Abstract
Background: Chinese herbal extract Number Ten (NT) is a dietary herbal formulation prepared
from rhubarb, ginger, astragalus, red sage and tumeric. This study tested the effectiveness of NT in
reducing body weight gain in rats.
Methods: Sixty female Wistar rats were fed a high fat diet and acclimated to gavage feeding. The
rats were divided into five treatment groups: (1) Control (n = 15); (2) NT-H (n = 15), 1.5 g/day;
(3) NT-L (n = 10), 0.75 g/day; (4) Pr-fed (n = 10), pair fed to NT-H; (5) d-FF (n = 10), d-fenfluramine
2 mg/kg. Ten rats per group were sacrificed on day 56. Weight, food intake, clinical chemistry and
body composition were evaluated. Five animals in the control and 1.5 g/day NT groups were left
untreated during a two week recovery period.
Results: The 0.75 g/day NT, 1.5 g/day NT, d-fenfluramine and pair fed groups gained 24.6%, 33.3%,
12.3% and 33.3% less than the control respectively (P < 0.0006). Leptin decreased 27.5% to 46.2%
in the treatment groups vs. control (P < 0.009). Parametrial fat decreased 14.1% to 55.5% in the
NT and pair fed groups vs. control (P < 0.006). The NT groups had soft stools, loss of hair around
the mouth and coloration to the urine and stool without evidence of blood or bilirubin (attributed
to chromogens in NT). There were no differences between groups in the clinical chemistry.
Conclusion: This study demonstrated the efficacy of NT in reducing weight gain in rodents.
Background
Herbal treatments have been found effective for major
diseases such as cancer, diabetes mellitus, and cardiovas-
cular disease [1-4]. We are looking for effective herbal
treatments for obesity. Obesity has a major influence on
the morbidity and life expectancy of people. Increasing
incidence of obesity suggests this epidemic of overweight
will only worsen in the future [5-7]. The absence of effec-
tive treatments for the grossly overweight, other than bar-
iatric surgery, has encouraged the search for new drugs
and drug targets that might be more effective in inducing
weight loss and/or preventing weight gain [8,9].
Traditional Chinese herbal products were reported to be
effective for the treatment of obesity [10,11]. One such, an
herbal decoction known as Number Ten (NT, which is not
a trade name) was reported in a published patent specifi-
cation to be effective in preventing obesity in rats when it
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was orally gavage fed. NT is developed from Rheum offici-
nale Baill. (Dahuang), Astragalus complanatus R. Br. (Shay-
uanjili), Salvia miltiorrhiza Bge. (Danshen), Curcuma longa
L. (Jianghuang), and Zingiber officinale Rosc. (Shengjiang).
The effect of NT to reduce body weight was reported in
otherwise normal rats that had been made very obese by
feeding a high energy diet [12] and also in obese rats that
had been treated with monosodium glutamate (to induce
hypothalamic lesions) [12]. In the former study, an
improvement in blood lipid and blood glucose levels was
also noted and in the latter one the obesity reducing effect
was shown in rats of both genders. In a third study, NT
was shown to be effective in attenuating the development
of obesity without affecting the gain in lean body tissue in
a young growing male rat that had been fed on high fat
diet to induce obesity [12].
Animal models have been used extensively to test the effi-
cacy of potential treatments for the prevention and treat-
ment of obesity. In particular, rodents that are fed on high
fat diet are thought to be an excellent model of obesity
where dietary environment is a major contributor [13-15].
Using a similar model, namely rat on high fat diet, we
report the efficacy of NT in preventing obesity and com-
pare its actions to those of d-fenfluramine, a known
anorectic [16,17].
Methods
Preparation of NT
The herbal decoction NT consists of a combination of
40% Rheum officinale Baill. (Dahuang), 13.3% Astragalus
complanatus R. Br. (Shayuanjili), 13.3% Salvia miltiorrhiza
Bge. (Danshen), 26–27% Curcuma longa L. (Jianghuang)
and 6–7% Zingiber officinale Rosc. (Shengjiang). The rhu-
barb root and stem were placed in a stainless steel pot
with water 6–8 times the herb's weight and a mixture of
the other four herbs were prepared in a similar manner.
The herbs were allowed to soak for eight hours. The water
in the pot with the four-herb mixture was boiled until the
volume was reduced by half. A cold rhubarb decoction
was then added to the four-herb mixture and heated to
just below boiling point for 20 minutes before cooling.
After filtering the large particulates from the decoction,
the remaining liquid was freeze-dried to a powder form,
producing 0.5 g of solids from 10 ml of liquid.
Animals
Sixty female Wistar rats (with an average weight of 220 g
at the beginning of the study) were housed individually in
hanging wire mesh cages. Room temperature was main-
tained at 22–24°C and light cycle was 12 hours with lights
out at 18:00. The animals were accustomed to handling
and daily gastric intubation over a one week period.
Treatments
Rats were divided into five experimental groups. All were
placed onto a high fat diet with 29% protein, 24% carbo-
hydrate and 30% fat by weight for 56 or 70 days (energy
density of diet = 4.78 kcal/g). Fresh food was placed in the
cages immediately before lights out. The five groups of
rats were tube-fed between 16:00 and 18:00 daily before
lights out with water (Control, 15 animals), 1.5 g of
freeze-dried NT powder (NT-H, 15 animals), 0.75 g of
freeze-dried NT powder (NT-L, 10 animals), water while
pair fed to NT-H (Pr-fed, 15 animals) and 2 mg/kg of d-
fenfluramine (d-FF, 10 animals) respectively. The experi-
mental protocol was approved by the Institutional Animal
Care and Use Committee and conformed to all the federal
guidelines.
Food intake
Food intake was recorded daily throughout the experi-
ment; body weight was recorded daily for the first 23 days
and twice a week from day 23 to day 56. Except for 5 ani-
mals in the control and the 1.5 g NT groups, all rats were
sacrificed by guillotine to collect trunk blood on day 56.
The remaining ten animals were sacrificed on day 70. The
parametrial and retroperitoneal fat pads were carefully
dissected free of surrounding tissues by a single investiga-
tor to ensure consistency of dissection. Other tissues were
individually dissected and weighed in a similar manner.
Blood chemistry
Trunk blood was collected from fed rats between 10:00
and 14:00 and serum was prepared. Serum cholesterol,
triglycerides, glucose, sodium, potassium, chloride, alka-
line phosphatase, alanine aminotransferase, aspartate
aminotransferase, creatine phosphokinase, gamma
glutamyl transpepdidase, amylase were assayed on a Beck-
man Coulter Synchron CX7 chemistry analyzer using
standard methods. Rat insulin, leptin and corticosterone
were assayed by commercial radioimmunoassays (Linco
Corp, San Diego, California, USA). Platelets, white blood
cell count, mean cell volume, hematocrit and hemoglobin
were also assayed on a Beckman Coulter HMX.
During the 56 days of the experiment, all rats were
observed daily by an animal technician, and weekly by a
veterinarian who was blind to the individual treatments
of each rat. Notations were made regarding their physical
activity/lethargy, fur condition, skin condition, eye condi-
tion, stools and 'others'.
Body composition
Body composition of the eviscerated carcasses was meas-
ured. The frozen carcasses were allowed to warm to room
temperature and then dried in a 60°C oven to constant
weight. The dried carcasses were homogenized repeatedly
to produce a homogeneous sample. A sample of thisChinese Medicine 2007, 2:10 http://www.cmjournal.org/content/2/1/10
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homogenate was used to assay protein (Kjeldahl analy-
sis), fat (Soxhlet extraction) and ash (combustion) for cal-
culation of body composition.
Statistics
Data were analyzed using the Statistical Package for Social
Sciences (SPSS) version 12. Weight, food consumption,
body composition, organ weights and clinical blood ana-
lytes were analyzed using one-way analysis of variance
(ANOVA) followed by a Scheffe Comparison of Means
analysis for unbalanced groups. After sample sizes were
balanced, an additional Bonferroni and Tukey Compari-
son of Means analysis was performed. Feed efficiency was
calculated from the amount of weight gained in grams per
gram of food consumed. Correlation was estimated by
Pearson's coefficients. The results with P values less than
0.05 were considered to be statistically significant.
Results
Body weight
The mean body weights of the five experimental groups
were similar at the start of the experiment. After the treat-
ment of 56 days, the body weights of all experimental
groups were significantly decreased compared to the con-
trol group (Figure 1). NT-treated groups and the d-fenflu-
ramine (d-FF) treated group lost weight during the first 48
hours of treatment. After this time, the weight gain of the
d-fenfluramine (d-FF) group paralleled that of the control
group. By contrast, the NT-treated groups continued to
gain weight at a slower rate than the control group. It
should also be noted that the rats that were pair fed to the
high dose NT group (NT-H) gained weight at the same
rate as the NT-H group (Figure 2). On day 56 of the treat-
ment, the rats administered low dose NT (NT-L) and high
dose NT (NT-H) had gained 24.6% and 33.2% less weight
than the control group respectively. The rats administered
d-fenfluramine (d-FF) gained 12.3% less weight than the
control group. After termination of treatment at 56 days,
there was no increase in the rate of weight gain of the NT
treated group (NT-H-R) over the next 14 days and their
weight difference to the control group (Control-R) was
maintained (Figure 1).
Food intake
The food intake of each group over the experimental
period is illustrated in Figures 2 and 3. The rats in the con-
trol group consumed significantly more total food than
the rats in any of the treatment groups over the 56-day
period. The rats administered d-fenfluramine (d-FF) con-
sumed less total food over the 56 day period than the con-
trol group. On the other hand, they consumed
significantly more food than those in other groups,
namely NT-H, NT-L and Pr-fed. The pair-fed rats ate
slightly less than the NT-H group during the experiment,
presumably due to spillage of the diet.
Feed Efficiency
In this study, feed efficiency is expressed as weight gain (g)
divided by weight of food consumed (Figure 4). The feed
efficiency of the d-FF group, which was still higher than
those of the NT-H, NT-L and Pr-fed groups, decreased sig-
nificantly compared to the control group. The feed effi-
ciencies of the NT-L and NT-H groups were 15.6% and
22.5% lower than that of the control group respectively.
The feed efficiency of the d-FF group was 7.8% lower than
that of the control group. Body weight gain and food
intake were closely correlated in individual experimental
groups (R2 and P values for each group respectively: Con-
trol 0.719, P < 0.05; NT-H 0.907, P < 0.01; NT-L 0.796, P
< 0.05; Pr-fed 0.694, P < 0.05; d-FF 0.798, P < 0.05) and
in the combined data (Figure 5).
Organ weights
There were no significant differences in the weights of the
kidney, spleen, liver, and gastrocnemius muscle among
the groups after the 56-day experimental period (data not
shown). The hearts of the rats in the control group were
significantly larger than those in all other groups. How-
ever, when the weight of the heart was taken as a percent-
age of the body weight of the respective rat, there were no
significant differences between the groups.
Parametrial and retroperitoneal white fat pads were signif-
icantly smaller in the NT-H group. They were also smaller
in the NT-L and the Pr-fed groups but were not signifi-
cantly different from either the NT-H group or the control
group (Figure 6). There were no differences between the
sizes of these adipose depots between the d-FF group and
the control group. In the rats allowed to recover for two
weeks after the end of treatment, the adipose depots
remained smaller than those in the control group despite
the fact that fat deposition increased significantly during
the 2-week recovery period. The size of the inter-scapular
brown adipose tissue depot was significantly reduced in
all experimental groups compared to the control group
(Figure 6).
Body composition
The percentage of total body fat was significantly reduced
in the NT-H group and a clear dose-related reduction with
NT treatment was observed (Figure 7), while body fat was
not significantly altered in any other experimental groups.
The percentage of body water, as expected, increased
slightly in the NT groups. There were no significant effects
of any treatment on body protein or ash (i.e. mineral con-
tent). Changes in body composition during the treatment
period could not be calculated because no rats were sacri-
ficed for analysis at time zero. However, from percentage
compositions and final body weights, we calculated the
differences in the body composition between the treat-
ment groups and control group at the end of the experi-Chinese Medicine 2007, 2:10 http://www.cmjournal.org/content/2/1/10
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ment. Virtually all the differences in body weight between
the NT-H group and control group can be attributed to the
difference in body fat between these two groups (Figure
8).
Serum hormones
Serum leptin was reduced significantly in all the treatment
groups compared to the control group (Figure 9). The dif-
ferences in leptin values continued during the 14-day
recovery period despite the withdrawal of NT, which
might be due to a modest weight gain during that period.
Serum leptin levels were correlated with percentage body
fat for each individual experimental group (R2 and P val-
ues for each group: Control 0.887, P < 0.001; Control-R
0.627, P < 0.05; NT-H 0.855, P < 0.01; NT-H-R 0.99, P <
0.001; NT-L 0.933, P < 0.001; Pr-fed 0.875, P < 0.001; d-
FF 0.769, P < 0.01) and the combined data (R2 = 0.708, P
< 0.001) (Figure 10).
Serum metabolites
Serum prepared from trunk blood obtained at time of sac-
rifice (day 56) was used for clinical chemistry assays. The
analyses included quantification of glucose, triglycerides,
cholesterol, alkaline phosphatase, alanine aminotrans-
ferase, amylase, aspartate aminotransferase, chloride, cho-
lesterol, creatinine phosphokinase, γ-glutamyl
transpeptidase, glucose, hemoglobin, hematocrit, mean
cell volume, platelets, potassium, sodium, triglycerides
and white blood cells. One-way ANOVA plus Scheffes'
Comparison of Means for each variable indicated that
there were no significant differences between any of the
serum analysis variables from the treatment groups and
control group, nor among the treatment groups.
Safety and toxicity
A small degree of alopecia during the first week of treat-
ment was observed around the chins of the rats in the NT-
H group. The alopecia disappeared within the next seven
days after the animal technician was advised to be more
scrupulous with the use of the intubation tube.
Rats in the NT treatment groups had yellowish urine
which stained fur around the genitalia. Urine was tested
negative for bilirubin. Rats in both NT-H and NT-L groups
had loose stools for the first few days. By the end of the
first week, the stools of the rats in the NT-L group were
well formed and their consistency appeared normal,
whereas the consistency of the stools of the rats in the NT-
H group still appeared softer than those in other groups.
Soft stools were observed among the rats in the NT-H
Change in body weight during the treatment and recovery phases Figure 1
Change in body weight during the treatment and recovery phases. Values represent the means for each group. The 
arrow indicates completion of the treatment period and the start of the recovery period for the two groups that were not sac-
rificed at that point. NT-H: high dose of NT; NT-H-R: high dose NT with a two week recovery period; NT-L: low dose of NT; 
Pr-fed: pair fed to NT-H group; d-FF: d-fenfluramine.Chinese Medicine 2007, 2:10 http://www.cmjournal.org/content/2/1/10
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group from time to time during the course of study. More-
over, the stools of the rats in both the NT-H and NT-L
groups appeared reddish throughout the duration of the
experiment. A test for hemoglobin was negative. The rats
in the NT-H group liked to rub and groom the fur around
their mouths after intubation, which was not observed in
other groups. During the recovery period when the NT
treatment was withdrawn, the color of the urine and
stools returned to normal and the rats stopped grooming
around the mouth. No other differences in activity/leth-
argy, fur condition, skin condition, eye condition or other
physical characteristics were observed.
Discussion
The results of this study demonstrate that NT was effective
in reducing body weight gain in rats that had been fed a
high fat diet to induce obesity. Rats in the high dose NT
(NT-H) and low dose NT (NT-L) groups gained 33.2%
and 24.6% less weight than those in the control group
respectively. These results are consistent with the range of
weight reductions in another study [12]. Furthermore,
weight reduction by NT appeared to occur in a dose-
dependent manner. Several interesting characteristics of
the weight reduction are as follows.
Firstly, the temporal changes in weight induced by NT and
d-FF were very different. Rats treated with d-FF showed the
classical response of rodents to anorectic drugs whereby
the majority of weight loss occurred in the first few days of
treatment, after which weight gain paralleled that of the
control group [16,18,19]. By contrast, the initial weight
loss and reduction in food intake were less pronounced
with NT treatment, instead a steady and continued reduc-
tion in weight gain throughout the study period was
observed.
Secondly, rats in the pair fed group had a similar reduc-
tion in weight gain and body fat as the high dose NT
group, therefore, reduction in weight gain with NT treat-
ment appears to be caused by reduction in food intake
rather than any metabolic effects. On the other hand, the
failure of NT treated rats to regain body weight during the
recovery period despite similar levels of food intake to the
control group would conversely suggest the possibility of
a small, prolonged metabolic effect. It also suggests that
the NT treatment may lead to a long lasting reduction in
body weight.
Thirdly, changes in body composition suggest that
decreases in body weight can be attributed to decreases in
body fat. Both the changes in the level of body fat and in
Mean daily food intake Figure 2
Mean daily food intake. The arrow indicates completion of the treatment period and the start of the recovery period for 
the two groups that were not sacrificed at that point. NT-H: high dose of NT; NT-H-R: high dose NT with a two week recov-
ery period; NT-L: low dose of NT; Pr-fed: pair fed to NT-H group; d-FF: d-fenfluramine. The change in food intake of every 
group except the Control-R group was statistically different from the control group with P < 0.05 (d-FF and NT-L) or P < 0.01 
(NT-H, Pr-fed and NT-H-R).Chinese Medicine 2007, 2:10 http://www.cmjournal.org/content/2/1/10
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the weight of the two fat pads are supportive of this inter-
pretation. The close correlation of serum leptin levels to
body fat provides great confidence in these data and once
again confirms the observation that serum leptin levels
are an excellent index of body fat levels [20]. There were
no changes in body protein despite the reduction in food
intake during this experimental period when the rats were
still growing.
Overall, the data suggest that the effects of NT on body
weight and body composition were mediated through
changes in food intake rather than metabolic effects. The
principal evidence for this is the similarity of the weight
changes between the NT-H group and the Pr-fed group. It
is important to recognize that the data on feed efficiencies
should not be interpreted as indicative of any metabolic
responses. Since the composition of the weight gain was
different between control and NT-treated groups, the feed
efficiency data underestimate the differences between
control and NT-treated rats. However, the decrease in feed
efficiency induced by NT reflects the differences in parti-
tioning of energy into fat stores in the presence of reduced
levels of food intake. The similarity in feed efficiency of
NT-H group to the pair fed group support this suggestion.
NT-treated rats protected their protein deposition at the
expense of reducing their fat deposition, an entirely nor-
mal response in the face of diminished energy availability.
The mechanism through which NT reduced food intake is
unknown. With any anorectic substances, it is important
to ensure that the reduction in food intake is not induced
through sickness or nausea. This is normally shown by
performing a conditioned taste aversion assay (CTA) with
the anorectic compound and comparing this to a known
aversive agent such as lithium chloride [21]. A CTA test
was not performed in the current study. There were no
physical symptoms to suggest that the rats treated with NT
were unwell or nauseated. On the contrary, the rats
remained active, alert and in good physical condition
throughout the study.
Correlation between food intake and body weight gain for all  animals except those in the two recovery groups Figure 5
Correlation between food intake and body weight gain for all 
animals except those in the two recovery groups. Total food intake Figure 3
Total food intake. Values represent mean ± standard devi-
ation (SD) for ten rats in each group except the two recov-
ery groups (n = 5). Intake for the recovery groups is for 70 
days whereas all other groups are for 56 days. * P < 0.05 
compared to control group; + P < 0.05 compared to control 
recovery (Control-R) group. NT-H: high dose of NT; NT-H-
R: high dose NT with a two week recovery period; NT-L: 
low dose of NT; Pr-fed: pair fed to NT-H group; d-FF: d-fen-
fluramine.
Feed efficiency over the 56 day or 70 day (recovery groups)  experimental periods Figure 4
Feed efficiency over the 56 day or 70 day (recovery 
groups) experimental periods. Values represent mean ± 
SD for ten rats in each group except the two recovery 
groups (n = 5). * P < 0.05 compared to control group. + P < 
0.05 compared to control recovery group. NT-H: high dose 
of NT; NT-H-R: high dose NT with a two week recovery 
period; NT-L: low dose of NT; Pr-fed: pair fed to NT-H 
group; d-FF: d-fenfluramine.Chinese Medicine 2007, 2:10 http://www.cmjournal.org/content/2/1/10
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Serum leptin levels Figure 9
Serum leptin levels. Values represent mean ± SD for ten 
rats in each group except the two recovery groups (n = 5). * 
P < 0.05 compared to control group. + P < 0.05 compared to 
control recovery group. NT-H: high dose of NT; NT-H-R: 
high dose NT with a two week recovery period; NT-L: low 
dose of NT; Pr-fed: pair fed to NT-H group; d-FF: d-fenflu-
ramine.
Body composition Figure 7
Body composition. Values represent mean ± SD for ten 
rats in each group except the two recovery groups (n = 5). 
NT-H: high dose of NT; NT-H-R: high dose NT with a two 
week recovery period; NT-L: low dose of NT; Pr-fed: pair 
fed to NT-H group; d-FF: d-fenfluramine.
Adipose tissue organ weights of rats Figure 6
Adipose tissue organ weights of rats. Values represent 
mean ± SD for ten rats in each group except the two recov-
ery groups (n = 5). * P < 0.05 compared to control group; + 
P < 0.05 compared to control recovery group. NT-H: high 
dose of NT; NT-H-R: high dose NT with a two week recov-
ery period; NT-L: low dose of NT; Pr-fed: pair fed to NT-H 
group; d-FF: d-fenfluramine.
Relative differences in body weight, body fat and body pro- tein Figure 8
Relative differences in body weight, body fat and 
body protein. Values represent mean ± SD for ten rats in 
each group except the two recovery groups (n = 5). NT-H: 
high dose of NT; NT-H-R: high dose NT with a two week 
recovery period; NT-L: low dose of NT; Pr-fed: pair fed to 
NT-H group; d-FF: d-fenfluramine.Chinese Medicine 2007, 2:10 http://www.cmjournal.org/content/2/1/10
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The rats treated with high dose NT that were allowed a two
week post treatment recovery period did not exhibit any
catch-up growth during this period. This finding may sug-
gest a continued response to NT or storage of the active
components within the body.
There were no clinical symptoms that would cause con-
cern in using this product in humans. The change in
appearance of stools was related to the dietary fat and
chromogens in the herbs. The negative testing for blood
and bilirubin along with the disappearance of these color
changes in the recovery period are consistent with this
hypothesis. The loss of hair around the mouth and nose
was possibly a result of the rats trying to wipe off residual
NT around the feeding cannula. This activity decreased
when the external part of the cannula was cleaned of NT
prior to intubation and ceased during the recovery period.
There is historical precedence for the use of rhubarb in the
treatment of obesity in China [10] although this may be
prohibited by regulatory bodies in some countries. While
these animal studies are encouraging for the possible use
of NT to treat human obesity, a recent clinical trial did not
demonstrate any efficacy probably owing to the dose lim-
iting gastrointestinal toxicity [22].
Conclusion
NT is an effective herbal formulation for reducing weight
gain in rats. Its effects are maintained throughout the
treatment period as shown in the present study. No toxic-
ity of NT was found in rats although gastric toxicity was
reported in humans.
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